{
  "id": 12443799,
  "title": "Why is Natera stock sliding today?",
  "url": "https://urgent.news/2026/10/06/why-is-natera-stock-sliding-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-06T18:29:39.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-natera-stock-sliding-today-93CH-4935080"
  },
  "original_language": "en",
  "account": "Natera's stock plummeted nearly 6.0% in afternoon trading after a swift reversal, soaring to a 52-week high of $437.41 before collapsing to $400.31. This downward trend, reminiscent of profit-taking following a technical peak, persisted despite a cascade of positive company-specific news. Citi raised its price target to $480 from $365, maintaining a Buy rating. Natera unveiled new Signatera data at the American Society for Radiation Oncology’s 2026 Annual Meeting, marking its inaugural participation at the ASTRO conference. Moreover, the AFT-70 NAVIGATE Phase III breast cancer trial, co-funded with Genentech and utilizing Natera's Signatera platform, was formally announced. The stock's performance, however, remained out of sync with the broader market, as both the S&P 500 and Nasdaq continued to climb. Recently disclosed SEC filings revealed insider selling by the CEO and the clinical diagnostics president, indicating a cautious sentiment. Despite the lack of macro headwinds or adverse central bank announcements, Natera's stock drop highlighted a classic scenario of 'buy the news, sell the fact': a stock that had surged significantly on strong catalysts eventually fell victim to aggressive profit-taking, driven by investors concerned about a valuation that far exceeded consensus targets and fundamental fair-value estimates.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}